ATAI heads into Thursday's earnings report with a striking disconnect: short sellers have cut positions at the fastest pace in months, yet the analyst community just staged its most coordinated downgrade wave in years.
The short-side capitulation this week is the loudest signal in the data. Short interest dropped 37% in a single session on August 11 — falling from roughly 27.9 million shares to 17.5 million — and is now down nearly 48% from a month ago to 8.2% of the free float. That unwinding follows a sustained squeeze: availability has swung from tight (under 150% through most of July) to extremely loose, hitting 999% on Tuesday. With cost to borrow holding at a negligible 0.55%, there is no friction left discouraging short covering. The ORTEX short score confirms the retreat, dropping sharply to 40.4 on August 11 from readings near 49 for most of the prior week. Bears who were pressing hard in early July have largely stood aside ahead of the print.
Options positioning tells a different story, and the contrast matters. The put/call ratio has climbed to 0.23 — a 52-week high — running above its 20-day average of 0.21. That sounds cautious, but the z-score is only 0.75, so this is a mild lean rather than genuine alarm. What is notable is the directional shift: in mid-July the PCR sat near 0.10, heavily call-skewed, reflecting the euphoria after the Eli Lilly partnership news. The slow drift toward puts over the past four weeks suggests options traders are quietly hedging gains into the event, not making an aggressive directional bet.
The Street has turned decisively more sceptical. Deutsche Bank downgraded to Hold and cut its target from $12 to $8 as recently as this morning — the most prominent name among at least seven firms that pulled Buy ratings between July 16 and now. Guggenheim, Jefferies, Needham, Jones Trading, Maxim, and Canaccord all moved to neutral stances in a compressed three-day window in mid-July, immediately after what appears to have been a clinical update. The consensus is now 3 Buys versus 11 Holds, with a mean target of $9.59 — roughly 33% above the current price of $7.21. HC Wainwright's target cut from $25 to $7.50 in late July stands out as particularly aggressive and likely reflects a fundamental reassessment of pipeline probabilities rather than a valuation trim. The price-to-book has expanded sharply, rising by 4.8 over the past 30 days on the back of the 39% monthly price gain, even as the company remains deeply loss-making with a P/E of -16 and EV/EBITDA of -17.
The institutional picture carries a notable recent flow. BlackRock added 18.7 million shares in a filing through July 31, building its stake to 6.9% of shares outstanding — a meaningful commitment from a passive-weight-adjusted buyer at a stock that was still trading well below current levels. State Street also added 7.1 million shares in the same reporting period. Founder-adjacent vehicle Apeiron Investment Group remains the largest holder at 14.6%, and their last disclosed activity was a large buy at $2.19 per share in August 2025 — now sitting on a substantial gain. Against that, insiders on the operating side have been consistent sellers: the COO, CMO, and a director all sold in June and July at prices between $4.51 and $5.00, taking profit well below the current level.
After the last three earnings-adjacent announcements, the stock moved -12.8%, -1.4%, and +5.0% on the following day. The five-day window has been less forgiving, with the June 4 event producing a -16% drift. Thursday's print — scheduled for after the close — arrives with the stock up 39% in a month, a freshly downgraded analyst consensus, and a short base that has largely cleared. Whether the remaining 8% short float adds fuel or stays quiet will depend on what the data release contains about VLS-01 and BPL-003, with the Eli Lilly milestone structure an additional focus for investors holding the name at elevated levels.
See the live data behind this article on ORTEX.
Open ATAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
